MacroGenics Inc. Stock
MacroGenics Inc. Stock
Pros and Cons of MacroGenics Inc. in the next few years
Pros
Cons
Performance of MacroGenics Inc. vs. its peers
| Security | Change(%) | 1w | 1m | 1y | YTD | 3y | 5y |
|---|---|---|---|---|---|---|---|
| MacroGenics Inc. | 0.930% | 1.278% | -7.254% | -63.075% | -61.016% | -80.183% | -93.467% |
| Ardelyx Inc. | 5.570% | 2.840% | 1.187% | 5.509% | 6.465% | 176.349% | -3.856% |
| Krystal Biotech | 0.330% | 3.678% | 18.962% | 25.776% | 37.057% | 193.803% | - |
| Evolus Inc | -4.200% | -1.724% | -8.065% | -47.706% | -45.714% | -18.571% | 88.742% |
sharewise BeanCounterBot
The analysis provided is generated by an artificial intelligence system and is provided for informational purposes only. We do not guarantee the accuracy, completeness, or usefulness of the analysis, and we are not responsible for any errors or omissions. Use of the analysis is at your own risk.MacroGenics, Inc. (NASDAQ: MGNX) operates in the Biotechnology & Medical Research industry, focusing on innovative therapies for cancer treatment. The financials reveal a company grappling with significant operational challenges but also charting a path through strategic investments and potential revenue growth. While the overall impression indicates distress in earnings and profitability, there are areas worth exploring, including cash management, investments in R&D, and future revenue potential that could influence the company’s recovery and growth.
Liquidity Position: MacroGenics ended 2023 with a cash balance of $100.96 million. This indicates a relatively healthy liquidity position that can help sustain operations in the near term, especially crucial for a biotech firm where cash flows can be irregular and dependent on clinical milestones and regulatory approval timelines.
Strategic Investments: The company reported capital expenditures of approximately $1.76 million while managing cash flows from financing activities of $150.36 million. This indicates an ability to raise funds, possibly for further development or marketing of their products, positioning MacroGenics to capitalize on future opportunities.
Comments
News
MacroGenics Revenue Doubles in Q2
MacroGenics (NASDAQ:MGNX), a biotechnology company focused on antibody-based cancer treatments, reported its second-quarter results on August 14, 2025. The release showed GAAP revenue of $22.2
